LEXSTON LIFE SCIENCES CORP.

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND NINE-MONTH PERIODS ENDED FEBRUARY 28, 2023 AND 2022

(EXPRESSED IN CANADIAN DOLLARS)

(Prepared by Management)

(UNAUDITED)

NOTICE OF NO AUDITORS' REVIEW OF
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an auditor has not performed a review of the condensed interim consolidated financial statements, they must be accompanied by a notice indicating that an auditor has not reviewed the condensed interim consolidated financial statements.

The accompanying unaudited condensed interim consolidated financial statements of Lexston Life Sciences Corp. (the "Company") have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these condensed interim consolidated financial statements in accordance with standards established by the Chartered Professional Accountants of Canada ("CPA Canada") for a review of interim financial statements by an entity's auditor.

LEXSTON LIFE SCIENCES CORP.

LEXSTON LIFE SCIENCES CORP.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Expressed in Canadian dollars)
(UNAUDITED)

	February 28, 2023 $	May 31, 2022 $
ASSETS		
Current assets		
Cash	**686,880**	590,494
Accounts receivable (Note 4)	**8,299**	37,565
Prepaid expenses and advances (Note 5)	**108,358**	187,387
Total current assets	**803,537**	815,446
Non-current assets		
Investment (Note 6)	**29,000**	29,000
Property and equipment (Note 8)	**63,597**	108,353
Total assets	**896,134**	952,799
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities		
Accounts payable and accrued liabilities	**8,917**	79,088
Total current liabilities	**8,917**	79,088
Shareholders' deficit		
Share capital (Note 9)	**4,163,662**	3,276,996
Share-based reserves	**944,521**	793,059
Deficit	**(4,220,966)**	(3,196,344)
Total shareholders’ equity	**887,217**	873,711
Total liabilities and shareholders’ equity	**896,134**	952,799

Nature of operations and continuance of business (Note 1)
Subsequent Event (Note 13)

Approved and authorized for issuance by the Board of Directors on April 20, 2023:

/s/ Clinton Sharples
Clinton Sharples, Director

/s/ Jagdip Bal
Jagdip Bal, Director

(The accompanying notes are an integral part of these condensed interim consolidated financial statements)

LEXSTON LIFE SCIENCES CORP.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Expressed in Canadian dollars)
(UNAUDITED)

	Three-month period ended February 28, 2023 $	Three-month period ended February 28, 2022 $	**Nine-month period ended February 28, 2023 $**	Nine-month period ended February 28, 2022 $
Revenues (Note 6)	**–**	81,325	**–**	256,287
Cost of sales	**–**	32,516	**–**	73,028
Gross profit	**–**	48,719	**–**	183,259
Operating expenses				
Advertising and promotion	**13,562**	103,915	**172,900**	188,715
Amortization (Note 7)	**6,630**	29,768	**22,834**	58,438
Bad debt expense	**–**	53,604	**–**	53,604
Consulting	**171,605**	68,079	**377,313**	103,079
Management fees (Note 11)	**61,325**	22,500	**130,825**	70,000
Office and miscellaneous	**3,943**	11,622	**11,302**	30,980
Professional fees	**13,961**	21,786	**76,790**	102,302
Regulatory and transfer agent fees	**25,020**	6,939	**56,834**	75,952
Rent	**8,931**	7,601	**24,767**	12,669
Research and development	**–**	41,299	**(19,167)**	113,992
Salaries and benefits (Note 11)	**–**	107,817	**19,415**	312,640
Share-based compensation (Note 11)	**–**	36,410	**129,886**	708,549
Travel and promotion	**–**	831	**–**	6,090
Total operating expenses	**304,977**	673,448	**1,003,700**	1,837,010
Net loss before other income/(loss)	**(304,977)**	(655,932)	**(1,003,700)**	(1,653,751)
Other income/(loss)				
Gain on settlement of debt	**–**	**–**	**–**	13,400
Loss on disposal of equipment (Note 11)	**–**	–	**(20,922)**	–
Net loss and comprehensive loss	**(304,977)**	(655,932)	**(1,024,622)**	(1,640,351)
Loss per share, basic and diluted	**(0.01)**	(0.04)	**(0.04)**	(0.17)
Weighted average number of shares outstanding, basic and diluted	**30,309,167**	11,606,755	**26,860,408**	10,960,464

(The accompanying notes are an integral part of these condensed interim consolidated financial statements)

LEXSTON LIFE SCIENCES CORP.
CONDENSED INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
(Expressed in Canadian dollars)
(UNAUDITED)

	Share capital				
	Number of shares	Amount $	Share-based reserves $	Deficit $	Total $
Balance, May 31, 2021	9,993,652	1,506,184	433,969	(876,130)	1,064,023
Issuance of common shares pursuant to the exercise of stock options	540,000	774,332	(355,332)	–	419,000
Issuance of common shares pursuant to the exercise of warrants	978,333	733,750	–	–	733,750
Shares issued pursuant to acquisition	234,742	269,953	–	–	269,953
Fair value of stock options granted	–	–	708,549	–	708,549
Net loss for the period	–	–	–	(1,640,351)	(1,640,351)
Balance, February 28, 2022	11,746,727	3,284,219	787,186	(2,516,481)	1,554,924
Fair value of stock options granted	–	(7,223)	5,873	–	(1,350)
Net loss for the period	–	–	–	(679,863)	(679,863)
Balance, May 31, 2022	11,746,727	3,276,996	793,059	(3,196,344)	873,711
Issuance of common shares pursuant to private placement	18,562,440	928,122	–	–	928,122
Share issue costs	–	(41,456)	21,576	–	(19,880)
Fair value of stock options granted	–	–	129,886	–	129,886
Net loss for the period	–	–	–	(1,024,622)	(1,024,622)
Balance, February 28, 2023	**30,309,167**	**4,163,662**	**944,521**	**(4,220,966)**	**887,217**

(The accompanying notes are an integral part of these condensed interim consolidated financial statements)

(Expressed in Canadian dollars)

	Nine-month period ended February 28, 2023 $	Nine-month period ended February 28, 2022 $
OPERATING ACTIVITIES		
Net loss	**(1,024,622)**	(1,640,351)
Items not involving cash:		
Amortization	**22,834**	58,438
Bad debt expense	**–**	53,604
Disposal of assets	**21,922**	–
Share-based compensation	**129,886**	708,549
Changes in non-cash operating working capital:		
Amounts receivable	**29,266**	(130,322)
Prepaid expenses and deposits	**79,029**	(291,125)
Accounts payable and accrued liabilities	**(70,171)**	(4,436)
Deferred revenue	**–**	23,300
Due to related parties	**–**	13,334
Net cash used in operating activities	**(811,856)**	(1,209,009)
INVESTING ACTIVITIES		
Purchase of equipment	**–**	(434)
Cash acquired from acquisition Zenalytic Laboratories Ltd.	**–**	15,460
Acquisition of Zenalytic Laboratories Ltd.	**–**	(50,000)
Investment in Psy Integrated Health Inc.	**–**	(75,000)
Net cash provided by investing activities	**–**	(109,974)
FINANCING ACTIVITIES		
Proceeds from exercise of stock options	–	419,000
Proceeds from exercise of warrants	–	733,750
Net proceeds from private placement	**908,242**	–
Net cash provided by financing activities	**908,242**	1,152,750
Change in cash	**96,386**	(166,233)
Cash, beginning of period	**590,494**	949,171
Cash, end of period	**686,880**	782,938
Non-cash investing and financing activities:		
Fair value of broker warrants issued	**21,576**	–
Fair of shares issued for acquisition	**–**	269,953
Transfer of fair value of stock options to share capital upon exercise	**–**	335,332

1. NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS

Lexston Life Sciences Corp. (the "Company") was incorporated on January 3, 2020 under the laws of the province of British Columbia. The address of the Company's registered and records of is 1150 – 789 West Pender Street, Vancouver, BC, V6C 1H2 and its principal place of business is 929 Mainland Street, Vancouver, BC V6B 1S3. On January 18, 2021, the Company changed its name to Lexston Life Sciences Corp. in conjunction with the Share Exchange Agreement (the "Agreement") with Egret Biosciences Inc. ("Egret").

On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious disease outbreak and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, leading to an economic downturn. The impact on the Company has not been significant, but management continues to monitor the situation.

During the nine-month period ended February 28, 2023, the Company announced that it entered into a natural resource property option agreement. This option agreement amounts to the change of business of the Company and is subject to the approval by the Canadian Securities Exchange and shareholders of the Company pursuant to Policy 8, Fundamental Changes and Changes of Business of the Exchange. The Company's wholly owned subsidiaries, Egret Bioscience Ltd. and Zenalytics Laboratories Ltd. suspended operations effective June 15, 2022. During the nine-month period ended February 28, 2023, the Company incurred a net loss of $1,024,622 (2022: $1,640,351) and has used net cash in operating activities of $811,856 (2022: $1,209,009). As at February 28, 2023, the Company has an accumulated deficit of $4,220,966 (May 31, 2022: $3,196,344).

The Company expects to incur further losses in the development of its operations. While the Company has positive working capital, the ability of the Company to carry out its business objectives is dependent on its ability to secure continued financial support from related parties, to obtain public equity financing, or to ultimately attain profitable operations in the future. If and when the Company can attain profitability and positive cash flows is uncertain. While the Company has been successful in securing financing in the past, there is no assurance that financing will be available in the future on terms acceptable to the Company.

These unaudited condensed interim consolidated financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and thus be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in these consolidated financial statements.

2. SIGNIFICANT ACCOUNTING POLICIES

Basis of preparation

These unaudited condensed interim consolidated financial statements have been prepared in accordance with IAS 34 – Interim Financial Reporting as issued by the International Accounting Standards Board ("IASB"). Accordingly, certain disclosures included in annual financial statements prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the IASB have been condensed or omitted and these unaudited condensed interim consolidated financial statements should be read in conjunction with the Company's audited annual financial statements for the year ended May 31, 2022.

2. SIGNIFICANT ACCOUNTING POLICIES (continued)

Principles of Consolidation

These unaudited condensed interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Egret Bioscience Ltd. ("Egret") and Zenalytic Laboratories Ltd. ("Zen"). The Company's unaudited condensed interim consolidated financial statements include the accounts of all subsidiaries subject to control by the Company. Control is achieved when the Company has the power to, directly or indirectly, govern the financial and operating policies of an entity so as to obtain benefits from its activities. Subsidiaries are fully consolidated from the date on which control is obtained and continue to be consolidated until the date that such control ceases. Intercompany balances, transactions, and unrealized intercompany gains and losses are eliminated upon consolidation.

Use of Estimates and Judgments

The preparation of these unaudited condensed interim consolidated financial statements in accordance with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited condensed interim consolidated financial statements and reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates. The unaudited condensed interim consolidated financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the unaudited condensed interim consolidated financial statements and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and the revision affects both the current and future periods.

Significant areas requiring the use of management estimates include the collectability of accounts receivable, carrying value of investment, the useful lives and carrying value of property and equipment and intangible assets, fair value of share-based compensation, and recoverability of unrecognized deferred income tax assets.

Significant judgments include:

- Assessment of whether the going concern assumption is appropriate which requires management to take into account all available information about the future, which is at least, but not limited to, 12 months from the end of the reporting period; and
- Judgment with respect to the assessment of fair value of investment in a private company. The fair value of common shares in a private company is determined by valuation techniques such as recent arm's length transactions, option pricing models, or other valuation techniques commonly used by market participants.

These unaudited condensed interim consolidated financial statements follow the same accounting policies and methods of application as the annual audited consolidated financial statements for the year ended May 31, 2022.

(Expressed in Canadian dollars)

3. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

The Company is exposed to various financial instrument risks and assesses the impact and likelihood of this exposure. These risks include liquidity risk, credit risk, price risk, currency risk and interest rate risk. Where material, these risks are reviewed and monitored by the Board of Directors.

Fair values

Assets and liabilities measured at fair value on a recurring basis were presented on the Company's condensed interim consolidated statement of financial position as at February 28, 2023 as follows:

	Fair Value Measurements Using			
	Quoted prices in active markets for identical instruments (Level 1) $	Significant other observable inputs (Level 2) $	Significant unobservable inputs (Level 3) $	Carrying Amount $
Investments	–	29,000	–	29,000

Fair value measurements of financial instruments are required to be classified using a fair value hierarchy that reflects the significance of inputs used in making the measurements. The levels of the fair value hierarchy are defined as follows:

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
Level 3 - Inputs for assets or liabilities that are not based on observable market data. comprehensive income or loss.

The fair values of other financial instruments, which include cash, accounts receivable, accounts payable and accrued liabilities, and amounts due to related parties approximate their carrying values due to the relatively short-term maturity of these instruments.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company currently settles its financial obligations out of cash. The ability to do this relies on the Company raising debt and equity financing in a timely manner and by maintaining sufficient cash in excess of anticipated needs. The Company has cash of $686,880 at February 28, 2023 (May 31, 2022 – $590,494) in order to meet short-term liabilities of $8,917 (May 31, 2022 – $79,088). There is no assurance that financing will be available or, if available, that such financing will be on terms acceptable to the Company. The Company monitors its risk of shortage of funds by monitoring the maturity dates of its existing liabilities. The Company's accounts payable are all due within one year.

Credit risk

Credit risk is the risk of potential loss to the Company if the counterparty to a financial instrument fails to meet its contractual obligations. The Company's credit risk is primarily attributable to its liquid financial assets which primarily is cash. The Company limits exposure to credit risk on liquid financial assets through maintaining its cash held with one of the largest credit unions in Canada. The carrying amount of financial assets represents the maximum credit exposure.

Foreign exchange rate and interest rate risk

The Company is not exposed to any significant foreign exchange rate or interest rate risk.

(Expressed in Canadian dollars)

3. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)

Capital management

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders.

The Company depends on external financing to fund its activities. The capital structure of the Company currently consists of cash, and equity comprised of issued share capital and share subscriptions receivable. The Company manages the capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may issue new shares through private placements, or sell assets to fund operations. Management reviews its capital management approach on a regular basis. The Company is not subject to externally imposed capital requirements.

4. ACCOUNTS RECEIVABLE

	February 28, 2023 $	May 31, 2022 $
Trade accounts receivable	**–**	29,518
Taxes receivable	**8,299**	8,047
	8,299	37,565

During the nine-month period ended February 28, 2023, the Company recorded an allowance for doubtful accounts of $nil (year ended May 31, 2022 - $135,964).

5. ADVANCES

The Company entered in a mineral property option agreement January 18, 2023. In order to exercise the option and earn the first 51% interest in the Dory Property, the Company, upon the acceptance by the Exchange of the Option Agreement and the change of business of the Company, has to:

a) pay to the Optionor $85,000 (advanced $76,000 in trust); and

b) issue to the Optionor a total of 250,000 common shares of the Company.

The Company will earn further 49% interest in the Dory Property making the total interest of the Company in the Property 100% by:

a) making a cash payment to the Optionor in the amount of $10,000 within one year from the date of the acceptance of the Option Agreement and the change of business of the Company by the Canadian Securities Exchange;

b) incurring expenditures on the Dory Property in the amount of $100,000 within one year from the date of the acceptance of the Option Agreement and the change of business of the Company by the Exchange; and

c) issuing to the Optionor a total of 250,000 common shares of the Company within one year from the date of the acceptance of the Option Agreement and the change of business of the Company by the Exchange. The option is subject to 2% net smelter return royalty in favour of the Optionor, 1/2 of which can be repurchased by the Company for $1,000,000.

(Expressed in Canadian dollars)

6. INVESTMENT

On July 7, 2021, the Company acquired 750,000 Class C non-voting common shares of Psy Integrated Health Inc. ("Psy Integrated"), a private company incorporated in the province of British Columbia, at $0.10 per share for $75,000, representing 13% of the total issued and outstanding shares of Psy Integrated and no voting rights, board representation, or involvement in the day-to-day nature of its operations. The Company's investment in Psy Integrated is recorded as FVTPL.

During the nine-month period ended February 28, 2023, the Company recorded an unrealized loss of $nil (year ended May 31, 2022 - $46,000) on its investment in Psy Integrated, and as at February 28, 2023, has a carrying value of $29,000 (May 31, 2022 - $29,000).

7. PROPERTY AND EQUIPMENT

	Computer equipment $	Laboratory equipment $	Total $
Cost:			
Balance, May 31, 2021	8,057	117,411	125,468
Additions	434	25,700	26,134
Balance, May 31, 2022	8,491	143,111	151,602
Disposals	(7,221)	(28,517)	(35,738)
Balance, February 28, 2023	**1,270**	**114,594**	**115,864**
Accumulated depreciation:			
Balance, May 31, 2021	1,137	10,130	11,267
Additions	2,789	29,193	31,982
Balance, May 31, 2022	3,926	39,323	43,249
Additions	939	21,895	22,834
Disposals	(3,937)	(9,879)	(13,816)
Balance, February 28, 2023	**928**	**51,339**	**52,267**
Carrying amount:			
Balance, May 31, 2022	4,565	103,788	108,353
Balance, February 28, 2023	**342**	**63,255**	**63,597**

(Expressed in Canadian dollars)

8. SHARE CAPITAL

Escrow Shares

Pursuant to an escrow agreement to be effective June 7, 2021, 4,260,000 common shares of the Company have been deposited into escrow for certain principal shareholders. Under the escrow agreement, 10% of the escrowed common shares are to be released (date of listing) and 15% will be subsequently released every 6 months thereafter over a period of 36 months. As of February 28, 2023, 1,917,000 (May 31, 2022 – 3,195,000) shares are held in escrow.

Share Issuances

Period ended February 28, 2023

(a) During the period ended February 28, 2023, the Company issued 18,562,440 units at $0.05 per unit for proceeds of $928,122, including 800,000 units issued to officers and directors of the Company for proceeds of $40,000. Each unit consisted of one common share and one share purchase warrant. Each warrant entitles the holder to purchase one common share for a period of five years at $0.075 per share. As part of the private placement, the Company paid finders' fees of $19,880 and issued 397,600 brokers warrants under the same terms and conditions as the warrants issued pursuant to the private placement. The value of the brokers warrants amounted to $21,575 based on the value of the equity instruments granted. This issuance cost was recorded as reduction in share capital and an increase in reserves.

Year ended May 31, 2022

(b) During the year ended May 31, 2022, the Company issued a total of 540,000 common shares for proceeds of $419,000 pursuant to the exercise of stock options which resulted in a transfer from share-based payment reserve to share capital of $348,109.

(c) During the year ended May 31, 2022, the Company issued 978,333 common shares for proceeds of $733,750 pursuant to the exercise of share purchase warrants at $0.75 per common share.

(d) On September 20, 2021, the Company issued 234,742 common shares with a fair value of $269,953 in connection with its acquisition of Zen.

9. SHARE PURCHASE WARRANTS

The continuity of share purchase warrants is summarized below:

	Number of warrants	Weighted average exercise price $
Balance, May 31, 2021	3,768,652	0.75
Exercised	(978,333)	0.75
Balance, May 31, 2022	2,790,319	0.75
Issued pursuant to private placement	18,562,440	0.075
Broker warrants issued pursuant to private placement	397,600	0.075
Balance, February 28, 2023	**21,750,359**	**0.16**

(Expressed in Canadian dollars)

9. SHARE PURCHASE WARRANTS (continued)

The following table summarizes the warrants outstanding and exercisable at February 28, 2023:

Number of warrants	Exercise price	Expiry date
953,320	$0.75	June 25, 2023
1,295,666	$0.75	July 14, 2023
541,333	$0.75	October 16, 2023
18,960,040	$0.075	July 4, 2027
21,750,359		

The $0.75 share purchase warrants are subject to an acceleration clause where they will expire within 30 days if the common shares of the Company are listed on a Canadian stock exchange and trade at a price of $2.00 per share or higher for ten consecutive business days. As at February 28, 2023, the weighted average remaining contractual life of all warrants outstanding was 3.84 years (May 31, 2022 – 1.15).

10. STOCK OPTIONS

The Company has a Stock Option Plan whereby stock options are granted in accordance with the policies of regulatory authorities at an exercise price equal to the market price of the Company's stock on the date of the grant and, unless otherwise stated, vest on the grant date and with a term not to exceed five years. Under the plan, the board of directors may grant up to 10% of the issued number of shares outstanding as at the date of the stock option grant.

	Number of options	Weighted average exercise price $
Outstanding, May 31, 2021	400,000	0.50
Granted	936,000	0.82
Exercised	(540,000)	0.78
Outstanding, May 31, 2022	796,000	0.69
Granted	3,000,000	0.05
Cancelled	(796,000)	0.69
Outstanding, February 28, 2023	3,000,000	0.05
Exercisable, February 28, 2023	3,000,000	0.05

Additional information regarding stock options outstanding and exercisable as at February 28, 2023 is as follows:

Stock options outstanding	Stock options exercisable	Exercise price	Expiry date
3,000,000	3,000,000	0.05	October 6, 2027
3,000,0000	**3,000,000**		

As at February 28, 2023, the weighted average remaining contractual life of all options outstanding was 4.60 years (May 31, 2022 – 3.88 years)

(Expressed in Canadian dollars)

10. STOCK OPTIONS (continued)

During the nine-month period ended February 28, 2023, the Company cancelled all options outstanding as at May 31, 2022. On October 6, 2022, the Company granted 3,000,000 (February 28, 2022 – 936,000) stock options to officers, directors, and consultants of the Company which vest immediately. The Company recorded share-based compensation in the amount of $129,886 (February 28, 2022 - $708,549) using the Black-Scholes option pricing model to estimate the fair value of the options granted using the following assumptions and assuming no expected dividends or forfeiture rates:

	Period ended February 28, 2023	Period ended February 28, 2022
Annualized volatility	130%	127%
Risk-free interest rate	3.49%	0.34%
Expected life	5 years	5 years

As at February 28, 2023, there was $nil (February 28, 2022 - $26,208) of unrecognized share-based compensation related to unvested stock options.

11. RELATED PARTY TRANSACTIONS

Key Management Compensation

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company's executive officers and Board of Director (including former) members. All related party transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

	Three-month period ended February 28, 2023 $	Three-month period ended February 28, 2022 $	**Nine-month period ended February 28, 2023 $**	Nine-month period ended February 28, 2022 $
Consulting fees	**22,500**	–	**42,500**	–
Management fees	**61,325**	22,500	**130,825**	70,000
Salaries and benefits	**–**	45,000	**18,023**	120,000
Share-based payments	**–**	8,365	**45,460**	145,498

(a) During the nine-month period ended February 28, 2023, the Company incurred $42,500 (February 28, 2022 - $nil) of consulting fees to a director.

(b) During the nine-month period ended February 28, 2023, the Company incurred $130,825 (February 28, 2022 - $70,000) of management fees to the Chief Executive Officer and Director.

(c) As at February 28, 2023, the Company owed $nil (May 31, 2022 - $6,923) to the former Chief Scientific Officer and former Director of the Company. The amount owing is unsecured, non-interest bearing, and due on demand. During the nine-month period ended February 28, 2023, the Company incurred $10,898 (February 28, 2022 - $67,500) of salaries and benefits to the former Chief Scientific Officer and former Director.

(d) During the nine-month period ended February 28, 2023, the Company incurred $7,125 (February 28, 2022 - $52,500) of salaries and benefits to a former director.

11. RELATED PARTY TRANSACTIONS (continued)

Key Management Compensation (continued)

(e) During the nine-month period ended February 28, 2023, the Company disposed of equipment to a former director of the Company with a net book value of $20,922 (February 28, 2022 - $nil) in lieu of notice of his termination.